Commentary
Video
Author(s):
Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss considering factors for immunotherapy agents in advanced biliary tract cancer.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Nab-Paclitaxel Plus SOC Chemo Fails to Improve OS in Newly Diagnosed Advanced Biliary Tract Cancer
Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress
FDA Approval of Tislelizumab Plus Chemo Offers a New Option in Advanced Gastric/GEJ Adenocarcinoma
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
Bezuclastinib Plus Sunitinib Elicits Preliminary Activity, Is Safe in Pretreated GIST
Revisit the Top Presentations and Biggest Data From the 2025 Gastrointestinal Cancers Symposium
High-Grade Cancer, But Not SVM, Is Associated With OS Disparities in Black Patients With Uterine Carcinoma
Dr Hillman on Identifying New Therapy Candidates in Adult-Type Granulosa Cell Tumor
Dr Secord on the National Academies of Sciences, Engineering, and Medicine’s Assessment of Women’s Health Research at the NIH
Molecular Subtyping Predicts Recurrence and Survival Benefits in Endometrial Cancer
Penn Medicine's Roberts Proton Therapy Center Celebrates 15 Years
CAR T-Cell Therapy Results in Secondary Primary Cancers in Approximately 4% of Patients
Real-World Analysis Shows Superior Efficacy With Cilta-Cel vs Ide-Cel in R/R Multiple Myeloma